Imclone systems (IMCL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL)

IMCL 0.159

0.0%

Oct 5 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (1663)	9/19/2001 7:05:05 PM
From: Oak Tree	Read Replies (1) of 2515

You know Tuck, it might still be great news for shorters. For some reason bristol has not had great judgement in a long time in the drugs it is purchasing. For example, endostatin -- you remember the cover of the NY times. My feelings about this C225 and its competition haven't changed. Remember, IMCL stillhas a 40% insider ownership. They have a drug that "might" help chemo work better -- it doesn't work on its own. They have a drug that attacks one of the EGFR receptors and works on only a subset of cancers. There are at least four receptors. There are already three EGFR drugs approved, some of which are easily manufactured (unlike C225). Other new EGFR drugs are approaching market. They will all probably be less expensive to make than C225. C225, the lead drug, is a flash in the pan. Given that Bristol now owns 20%, it is likely that no one will "buy" the company. THere is a lot of hype around it. That might sell it but I'm not sure -- doctors can be quite fickle. Its all a matter of nerves and time. I still think its likely to get over-hyped and will be in for a big crash.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next